MabVax Therapeutics

company

About

MabVax is a biopharmaceutical company focused on the commercialization of proprietary anti-cancer immunotherapies.

  • 11 - 50

Details

Last Funding Type
Grant
Last Funding Money Raised
$1.75M
Industries
Biotechnology,Medical,Pharmaceutical
Founded date
Jan 1, 2006
Number Of Employee
11 - 50
Operating Status
Active

MabVax is a clinical stage biopharmaceutical company focused on the commercialization of proprietary anti-cancer immunotherapies resulting from two integrated and successful technology platforms. The first is a series of vaccines developed at Memorial Sloan-Kettering Cancer Center (MSKCC) and licensed to MabVax. Two of the company’s lead cancer vaccines are currently undergoing proof of concept Phase II multi-center clinical trials for the treatment of soft tissue sarcoma and ovarian cancer. Both trials have received $2MM or more in federal grant monies. The second is a human antibody discovery platform developed internally and based on the protective immune responses generated from patients who have been successfully immunized against targeted cancers with the licensed vaccines. The company’s lead human antibody candidate is undergoing preclinical evaluation for development against colon, pancreatic and breast cancers and has received $1.1MM in federal grant monies.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
3
$15M
MabVax Therapeutics has raised a total of $15M in funding over 2 rounds. Their latest funding was raised on Sep 25, 2013 from a Grant round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Sep 25, 2013 Grant $1.75M 1 Detail
Nov 20, 2012 Series B $5.25M 1 Numoda Capital Innovations Detail
Feb 27, 2008 Series A $8M 1 GBP Capital Detail

Investors

Number of Lead Investors
Number of Investors
2
3
MabVax Therapeutics is funded by 3 investors. Numoda Capital Innovations and GBP Capital are the most recent investors.
Investor Name Lead Investor Funding Round
Numoda Capital Innovations Yes Series B
GBP Capital Yes Series A
National Institutes of Health Grant